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AdolescentsSummary Objectives: Recent development of serogroup B meningococcal (MenB) vaccines
highlights the importance of pharyngeal carriage data, particularly in adolescents and young
adults, to inform implementation strategies. We describe current UK carriage prevalence in
this high risk population and compare methods of carriage detection.
Methods: In this multisite study, pharyngeal swabs were collected on 3e4 occasions over 6e12
months, from 1040 school and university students, aged 10e25 years. Meningococcal carriage
was detected by standard culture combined with seroagglutination or PCR of cultured isolates,
or by direct PCR from swab. The factor H binding protein (fHBP) variants present in meningo-
coccal isolates were determined.
Results: Meningococcal serogroups B and Y were most common, with carriage up to 6.5% and
5.5% respectively, increasing throughout adolescence. Identification by seroagglutination was
often unreliable, and the sensitivity of direct PCR detection was 66% compared to culture com-
bined with PCR. Of MenB isolates, 89.1% had subfamily A variants of fHBP. The acquisition rate
of MenB carriage was estimated at 2.8 per 1000 person-months.
Conclusions: If vaccination is to precede the adolescent rise in MenB carriage, these data sug-
gest it should take place in early adolescence. Studies assessing vaccine impact should use mo-
lecular methods to detect carriage.
ª 2015 The Authors. Published by Elsevier Ltd on behalf of the The British Infection
Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
C.A. Jeppesen et al.Introduction
Neisseria meningitidis remains a leading cause of meningi-
tis and septicaemia globally. There are 700e1200 cases of
invasive disease annually in the UK with a case fatality
rate of 5e15%.1,2 Invasive disease is almost exclusively
due to 6 capsular serogroups (A, B, C, W, X or Y) and effec-
tive capsule-based glycoconjugate vaccines are currently
available for the prevention of A, C, W and Y infection.3 Se-
rogroup B meningococcus (MenB) now accounts for 80e90%
of invasive disease in the UK,2,4 65% across Europe,5 and
30% in North America.6 The MenB capsule has a structure
identical to human polysialic acid and is therefore poorly
immunogenic, which has historically hampered vaccine
development. Recently, a MenB vaccine based on four sub-
capsular antigens (4CMenB, ‘Bexsero’, Novartis, Italy) has
been licensed in Europe while a vaccine composed of two
lipidated factor H binding proteins (bivalent rLP2086, ‘Tru-
menba’, Pfizer, USA) has been licensed in the USA.
The human pharynx is the only effective reservoir for N.
meningitidis, where it is carried as a commensal. Carriage
prevalence is age-related with carriage rates of up to
20e50% being reported in late adolescence.7 Carriage is
also associated with social risk factors, including visiting
night clubs, kissing, smoking, and living in closed commu-
nities such as military or university residences.8e10 The
relationship between carriage and disease is complex.
Most disease is caused by a limited number of ‘hyperinva-
sive’ strains, although these are commonly carried harm-
lessly, and pharyngeal isolates are often non-pathogenic
strains.11 Nonetheless, carriage data remain invaluable for
predicting disease epidemiology, and a vaccine which re-
duces carriage of invasive strains is likely to confer a herd
immunity effect, as has been seen with meningococcal se-
rogroup C (MenC) conjugate vaccines.12
The aim of this study was to address the relative paucity
of recent information about carriage in UK adolescents, by
sequentially collecting posterior pharyngeal swabs fromstudents at secondary school (typically attended from 11 to
18 years of age in the UK) and first year of university. As
both MenB vaccines include a recombinant factor H binding
protein (fHBP) component - a meningococcal virulence
factor which aids evasion of innate immunity - the study
characterised the fHBP variant type of all meningococci
isolated to add to epidemiological data on current strains
circulating in the UK. In considering the likely need to
assess the impact of vaccination on carriage in future
studies, the study also explored laboratory methodologies
for detecting carriage.
Methods
Study design and population
A longitudinal epidemiological study was performed to
collect pharyngeal swabs from secondary school and first
year university students, aged 10e25 years, during a 6e12
month period. Participants were enrolled and first swabbed
between MarcheMay 2011, across 13 secondary schools and
5 universities from 4 recruiting sites in the UK (Oxford,
London, Bristol and Southampton). The study was approved
by National Research Ethics Service Committee South Cen-
tral (Oxford B: 10/H0605/80). Written informed consent
was obtained from participants over the age of 18 and from
their parent(s) or legal guardian (s) (with the child’s assent)
below this age. Approximately equal numbers were to be
recruited in each of 5 age cohorts: 10e12, 13e14, 15e16,
17e18 and 19e25 years old.
The second study visit occurred two months after enrol-
ment (during MayeJuly 2011), at which time any additional
participants required were enrolled to fulfil the target
sample size. The third visit of the main study period
occurred 6 months after initial enrolment period (Septem-
bereOctober 2011). Students who were in their penultimate
school year at enrolment (year 12), were invited for an
additional visit 12 months after enrolment (FebruaryeMarch
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Pharyngeal samples were collected at each visit.
Participants completed a questionnaire concerning risk
factors for carriage such as smoking, kissing and numbers in
household. The participant’s history of any recent antibi-
otic usage and meningococcal vaccination was also sought
from the participants or their parents and participants
excluded if they had ever received an investigational
vaccination against MenB infection. The primary objective
was to estimate the prevalence of MenB throat carriage in
secondary school and first year university students, as
determined by seroagglutination of cultured isolates. Sec-
ondary and exploratory endpoints included estimation of
the prevalence of non-B serogroups; comparison with
prevalence when measured by 2 other microbiological
methods, namely PCR of cultured isolates and direct PCR
from swab transport medium; fHBP variant characterisation
of the isolates collected; and estimation of carriage
acquisition rates from the longitudinal data.Sampling and bacterial identification
Two pharyngeal samples were collected simultaneously
through the mouth using two cotton swabs held together,
by gently rubbing the tonsils (or tonsillar fossae) and the
posterior pharynx. One swab was plated immediately onto
ThayereMartin improved medium, and incubated within 3 h
at the local laboratory, at 37 C in 5% carbon dioxide.
Culture plates were examined at 24, 48 and 72 h for
suspected colonies of N. meningitidis; single representative
colonies were subcultured onto Columbia Blood Agar then
gram-stained and tested for oxidase-positivity. Identity as
N. meningitidis was confirmed by commercial biochemical
tests (API-NH, bioMerieux).
The second swab was placed directly in transport me-
dium (Digene Sample Transport Medium, Qiagen), and
frozen for later PCR analysis.
The serogroup of cultured meningococcal isolates was
assigned by 2 methods:
i) Seroagglutination. At local site laboratories, seroagglu-
tination of several emulsified colonies was performed by
slide agglutination with commercial antisera based on
whole cell preparations for serogroups A, B, C, D, E,
W, X, Y and Z (Difco, BD Diagnostic Systems, Sparks,
Maryland). Valid results were indicated by clumping
with only one antiserum and lack of clumping in buffer
alone (autoagglutination).
ii) Isolate PCR. Purified isolates were frozen on cryovial
beads (Microbank, Pro-lab) at 70 C. Frozen isolates
were recovered, inspected for purity, then a 10 mL loop-
ful of bacteria was solubilized in 1 ml 1X Phosphate Buff-
ered Saline and diluted to provide a 1e5  105 cfu/mL
sample for PCR analysis in Digene Sample Transport Me-
dium. Real-time PCR (RT-PCR) assays for detecting se-
rogroup specific capsule genes was conducted at PPD
(Pharmaceutical Development LLC, Wayne, PA).
A third method of carriage detection and serogroup
identification, assessed for MenB only given its importance
for contemporary vaccine studies, was direct swab PCR. Inthis approach, DNA extraction and RT-PCR analysis was per-
formed on 0.25 ml aliquots of transport medium from the
second pharyngeal swab, bypassing the step of organism
culture and isolation.
Real time PCR assay
RT-PCR assays were designed to both detect and serogroupN.
meningitidis. Detection was achieved by amplification of the
genes for surface protein porin A (porA, present in almost all
strains of N. meningitidis) and ctrA (common to all meningo-
coccal capsule operons regardless of the serogroup). Concur-
rently, genetic serogroup was assigned by a set of RT-PCR
assays which relied on intrinsic differences in synthesis path-
ways between capsule type, and/or genetic diversity in
sequence for shared genes between serogroups, for example
the serogroup-specific sialic acid biosynthesis gene siaD was
used to detect MenB (Rojas, E. et al. manuscript in prepara-
tion). The primers used were based on published sequence
data, and all assays were qualified in accordance with guide-
lines published by the International Conference on Harmoni-
sation13,14 and United States Food and Drug Administration,15
by Rojas et al. (manuscript in preparation). For further de-
tails, see Supplementary appendix 1.
Factor H binding protein sequence analysis
Determination of the fHBP variant type for all isolates was
performed by nucleic acid sequencing using methods
described previously.16
Statistical methods
A sample size of 1000e1200 subjects was chosen on the
basis of confidence interval estimates. A conservative
estimate for MenB prevalence of 2% would result in 95% CI
of 1.2% and 3.1% with sample size 1000, and 1.3%e3.0% with
sample size 1200, using the Clopper-Pearson exact
method.17 The expected size of these confidence intervals
was considered small enough to provide meaningful esti-
mates of prevalence.
This study was a descriptive epidemiological study;
endpoints are estimates without formal hypothesis testing.
For prevalence estimates, the numerator was the total
number of positive results across all visits, and the denom-
inator was the total number of times participants were
tested across all visits. Exact 2-sided 95% confidence
intervals (Clopper-Pearson) were calculated. For demo-
graphic analysis the intention to treat population was
used, defined as all enrolled subjects. For longitudinal
analysis, the number who had supplied at least one sample
was used. The proportions of subjects with changes in
meningococcal carriage were calculated with exact 95%
confidence intervals using the F distribution.
Acquisition rate was the number of new meningococcal
carriage cases (acquisitions) occurring during the study,
divided by the total person-time of all initially negative
subjects. Due to anticipated small numbers, data from all
age groups were pooled. Any acquisition was assumed to
have occurred at the timepoint halfway between
assessments.
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The study enrolled 1040 participants in total, including 59
during the second recruitment period at the time of visit 2,
although not all participants attended all visits (Fig. 1).
The composition of the participants by age is shown in
Table 1. Most participants were Caucasian (76%), and
55.8% were female. Antibiotic use in the preceding 2
weeks was low, between 2.2 and 3.6% of participants at
visits 1e4.
Overall B and Y were the most prevalent serogroups
detected. Carriage rates by age cohort are shown in Fig. 2
across all visits. Prevalence at each visit is plotted in
Supplementary Fig. 4. Carriage of any meningococcus
ranged from 3.9% in the youngest to 26.5% in the oldest
cohort by seroagglutination method, or from 4.1% to
24.5% by isolate PCR.Figure 1 Summary of enrolment and disposition of study particip
ary school (year 12) were invited to participate in follow-up sampCarriage prevalence of MenB
Prevalence of pharyngeal MenB carriage was similar in age
cohorts 10e12 and 13e14, with a maximum prevalence of
1.5% by any method (Fig. 2A). Carriage was higher in the
older age cohorts, with highest prevalence in the 19e25
age cohort: 3.6%, 6.5% and 6.9% by seroagglutination,
isolate PCR and direct swab PCR, respectively.
Carriage prevalence of other meningococci
Carriage of serogroup Y meningococcus (MenY) reached
similar prevalence to MenB (Fig. 2C), whereas carriage of
MenC was extremely low, particularly when determined
by isolate PCR (isolated on only 3 occasions in the entire
study). Serogroups X and W were each detected in no
more than 2.0% of any age cohort at any visit, by eitherants. All students enrolled in their penultimate year of second-
le collection period four, 12 months after enrolment.
Table 1 Number of participants who submitted an pharyngeal sample during each period of sampling, by age at enrolment.
Visit number Period of collection Number of participants swabbed Age at enrolment Male n (%) All
Visit 1 MarcheMay 2011 977 10e12 years 110 (55%) 200
13e14 years 90 (54%) 169
15e16 years 87 (48%) 182
17e18 years 85 (34%) 254
19e25 years 54 (31%) 172
Visit 2 MayeJuly 2011 877 (including 59 newly enrolled) 10e12 years 104 (55%) 189
13e14 years 103 (52%) 197
15e16 years 85 (48%) 176
17e18 years 72 (35%) 205
19e25 years 32 (29%) 110
Visit 3 SepteOct 2011
(new academic year)
918 10e12 years 109 (55%) 197
13e14 years 104 (53%) 198
15e16 years 85 (48%) 176
17e18 years 70 (34%) 207
19e25 years 43 (31%) 140
Visit 4 FebeMarch 2012 166 15e16 years 18 (33%) 54
17e18 years 40 (36%) 112
The study enrolled 1040 students from secondary school and first year of university across 4 study sites, although not all participants
attended all visits. Numbers recruited from Oxford (273 participants), Southampton (257), London (243), and Bristol (267) were similar.
Meningococcal carriage in adolescents 47seroagglutination or isolate PCR (data not shown), and no
genetically-confirmed serogroup A (MenA) was detected.
Comparison of microbiological methods
Fig. 2 demonstrates substantial variation in detection of N.
meningitidis by different microbiological methods, with
carriage prevalence by seroagglutination generally lower
than by isolate PCR or direct swab PCR. MenC however
was detected more frequently by seroagglutination than
by isolate PCR; the lack of genetic confirmation renders
these probable false positive agglutination reactions.
As an illustration, the Venn diagram Fig. 3 shows the dis-
crepancies for MenB detection by the three methods used.
Of the 92 samples assigned MenB by isolate PCR, 59 (69%)
were positive by direct swab PCR and only 44 (48%) by se-
roagglutination. Seven samples were positive for MenB by
seroagglutination only, and were found to be false posi-
tives: 5 of these could not be confirmed as N. meningitidis
in the central laboratory and 2 were MenY by PCR. Twenty-
five samples were positive by direct swab PCR only. In 19 of
these no N. meningitidis was isolated at the site laboratory
or confirmed at the central laboratory, and 6 grew a non-
MenB serogroup by isolate PCR. Over the 2899 sample pairs,
the sensitivity and specificity of direct swab PCR relative to
isolate PCR were 0.66 and 0.99 respectively.
The detection of non-MenB serogroups also demon-
strated discrepancies between the two methods compared
for these serogroups (seroagglutination and isolate PCR)
(Table 2). Seroagglutination frequently assigned a se-
rogroup which did not correspond with the PCR genogroup.
In approximately 6% (nZ 22) of isolates, the isolate PCR
assay was positive for multiple serogroup targets. To
investigate this, the purity of these isolates was assessed
post hoc by dilution and subculture to produce 10 daughtercolonies which were genetically compared by porA geno-
typing. By this approach, some samples submitted by site
laboratories were found to be mixed. Sequencing of siaD
was performed on all MenB isolates to verify the RT-PCR re-
sults, and this revealed sequence diversity at the primer
site which necessitated use of a second set of primers to
enable detection of all MenB isolates.
Characterisation of fHBP variants
fHBP variants for all meningococcal isolates were analysed.
Variants are divided in two immunologically distinct sub-
families, A and B.16 Of isolates identified as serogroup B by
PCR (n Z 92), the majority (89.1%), belonged to subfamily
A, and the most common sub-family variants were A05
(27.2%), A22 (27.2%) and A12 (15.2%), although some varia-
tion was noted between the four geographical study sites
(Table 3).
Changes in carriage within individuals
In view of the discrepant results mentioned earlier, analysis
of carriage acquisition was based on isolate PCR data.
Among participants initially negative for MenB carriage at
enrolment, 1.9% (95% CI: 1.1, 2.9) became MenB carriers
during the 6 month main study period. Of those who were
initially MenB carriers, 48% (95% CI: 33, 63) became
negative during the study period. This equates to an
estimated acquisition rate of 2.8 per 1000 person-months
by isolate PCR, pooling data from all age groups.
When individual participants are followed longitudinally
across visits, 53/1039 (5.1%) were MenB carriers at any
time, of whom 53% (28/53) were carriers at more than one
visit and 45% (24/53) at two or more consecutive visits.
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Figure 3 The number of MenB positive results across all
pharyngeal samples collected, as detected by 3 laboratory
methods: seroagglutination, isolate PCR, and direct swab
PCR. Of 123 samples in which MenB was detected by any of
the 3 methods used, the number positive by one or more
methods is depicteda.
a Two direct swab PCR samples had insufficient volume for
testing (both were isolate PCR positive and seroagglutination
negative).
Meningococcal carriage in adolescents 49Carriage of MenY was acquired and lost with similar
frequency to MenB: 2.5% (95% CI:1.6, 3.6) became carriers
during the study, and 51% (95% CI:35, 67) of initial carriers
became negative.Discussion
This is the largest contemporary study of meningococcal
carriage through the second decade of life. We found MenB
and MenY to be the most commonly carried serogroups,
with prevalence reaching 6.5% for MenB and 5.5% for MenY
in the 19e25 age cohort, by isolate PCR. Carriage rates in
our 19e25 cohort are similar to those found in a recent
vaccine study by Read et al. in which 3000 UK university
students had baseline MenB prevalence of 9% and MenY
prevalence of 7%, using a combined serogroup and gen-
ogroup assignment strategy.18 In younger adolescents our
study prevalence of any meningococcal carriage was lower
than estimated by a European meta-analysis,7 which pre-
dicted carriage of 7.7% in 10 year olds, rising to 23.7% in
19 year olds, but the authors comment that many studies
included in that analysis may have been subject to recruit-
ment bias.
The largest previous meningococcal carriage study in the
UK took place around the introduction of a MenC vaccine
into the UK childhood immunisation schedule in 1999, which
was accompanied by a catch-up campaign for all aged
below 18 years.12,19,20 Carriage prevalence in 14,000 ado-
lescents aged 15e19 years immediately pre-vaccination
was 5.6% for serogroup B, 1.7% for serogroup Y, and 0.98%Figure 2 Prevalence estimates of meningococcal carriage by age
MenB carriage as detected by 3 laboratory methods: seroagglutina
PCR’) and RT-PCR of swab transport medium (‘direct swab PCR’). B
gidis carriage and E carriage of any meningococcus as detected by
confidence intervals.
a For the isolate PCR method, non-groupable was defined as a positiv
assays (ie A, B, C, E, X, W, Y and Z).for serogroup C, using PCR methodology to assign se-
rogroup. Two years later, carriage of serogroup C had drop-
ped to 0.5% (and 0.09% by seroagglutination). Our data
confirm that vaccination has been effective in maintaining
very low carriage of serogroup C. This is likely to be due
to a combination of persistent immunity among previously
immunised individuals and herd immunity.21 From knowl-
edge of UK MenC vaccine coverage it is expected that 85%
of participants would have received a single dose of MenC
vaccine in 1999/2000.22
The high prevalence of MenY is in keeping with recent
literature, which has shown increasing MenY carriage over
the last decade. Two studies in a UK university, 10 years
apart, demonstrated a significant rise in MenY carriage in
incoming students from 1.7% in 1997 to 2.9% in 2009.8,23
Carriage in the equivalent age cohort (17e18 years) in our
study was 4.5% by isolate PCR. This may reflect a further
rise in MenY, or geographical variation; the latter should
be countered by our study’s multisite design. Over the
same decade, MenY invasive disease has more than doubled
in the UK,2 although provisional data from 2013 suggests
that it still accounts for only 10.4% of cases (14% in 15e19
year olds).24 The peak incidence of MenY disease in the
UK is among those over 65 years of age, in contrast to other
serogroups, although a lesser peak in 15e19 year olds has
been observed.25 Of interest, the USA saw a dramatic rise
in the proportion of invasive disease caused by serogroup
Y in the 1990s, from 2% to the current rate of approximately
30%.26 There is evidence that the proportion of cases due to
MenY is also rising in other European countries,27 although
in the limited contemporary carriage data from across Eu-
rope, MenB is generally dominant.28
The distribution of meningococcal carriage across the
age cohorts that were sampled shows a gradual rise in later
adolescence, and accords with findings from a large meta-
analysis of studies.7 Any immunisation campaign designed
to reduce pharyngeal carriage of MenB (or MenY), and
thereby induce herd immunity, should aim to immunise
prior to this rise, i.e. in the early teenage years or before,
in order to prevent acquisitions and interrupt transmission.
There are limited data on whether new MenB vaccines,
based on non-capsular antigens, reduce carriage,29 yet the
effectiveness and cost-benefit of a MenB vaccination pro-
gramme may depend to a significant degree on this factor.30
A trial that evaluated whether 4CMenB had an impact on
carriage suggested its effect may be modest.18 The reasons
for this are uncertain, but vaccine trial participants mixed
with an unvaccinated population and therefore the effect
on carriage might be expected to be smaller than in the
setting of an immunisation programme. In addition, the
trial did not report how well the vaccine antigens matched
the strains of meningococcus circulating in that population.
It is not yet clear which subcapsular antigens might becohort (at enrolment), of selected serogroups. A. Prevalence of
tion of cultured isolates, RT-PCR of cultured isolates (‘isolate
Prevalence of MenC, C MenY, and D non-groupablea N. menin-
seroagglutination, and by isolate PCR. Error bars indicate 95%
e porA or ctrA result, but negative RT-PCR for all group-specific
Table 2 Discrepancies between assignment of serogroup according to seroagglutination and RT-PCR of cultured isolates, for
all swab cultures that were positive by either method.
Isolate PCR result Seroagglutination result
A B C D E W X Y Z Non-groupable
A 0 0 0 0 0 0 0 0 0 0
B 4 44 5 3 0 1 0 7 1 30
C 0 0 0 0 0 0 0 0 0 3
Da e e e e e e e e e e
E 1 0 5 0 17 1 1 4 1 31
W 0 0 1 1 1 9 0 1 0 7
X 0 1 2 0 0 0 1 1 0 5
Y 1 3 1 1 1 2 0 61 0 30
Z 0 0 0 1 1 0 1 0 1 10
Non-groupableb 1 1 12 2 2 3 2 6 1 46
No growthc 0 4 0 0 0 0 0 0 0 5
Negatived 0 1 1 0 0 0 0 0 0 2
Numbers in bold were concordant between the two assays.
a Serogroup D was only tested for by seroagglutination, not by isolate PCR.
b For the isolate PCR method, non-groupable was defined as a positive porA or ctrA result, but negative RT-PCR for all group-specific
assays (ie groups A, B, C, E, X, W, Y and Z).
c No growth at central laboratory.
d Isolate negative for porA and ctrA at central laboratory i.e. not confirmed as N meningitidis.
50 C.A. Jeppesen et al.responsible for any effect on pharyngeal carriage of MenB
vaccines, but the proportion of strains potentially ‘covered’
would depend on the antigenic types expressed by carriage
strains, and their similarity to vaccine antigens.31Table 3 Factor H binding protein variants among all serogroup
had successful sequencing of the fHBP gene, over entire study pe
Number of MenB isolates Oxford Southampto
24 14
Subfamily A 23 (95.8%) 11 (78.6%)
A05 4 (16.7%) 6 (42.9%)
A22 14 (58.3%) 2 (14.3%)
A12 4 (16.7%) 2 (14.3%)
A19 0 0
Subfamily B 1 (4.2%) 3 (21.4%)
B24 0 0
B03 0 2 (14.3%)
B204 0 0
B98 1 (4.2%) 0
Number of non-B isolates 86 47
Subfamily A 60 (69.8%) 26 (55.3%)
A15 31 (36.0%) 10 (21.3%)
A73 3 (3.5%) 5 (10.6%)
A103 6 (7.0%) 5 (10.6%)
A19 3 (3.5%) 2 (4.3%)
Subfamily B 23 (26.7%) 17 (36.2%)
B09 13 (15.1%) 14 (29.8%)
B16 7 (8.1%) 2 (4.3%)
B03 2 (2.3%) 1 (2.1%)
B06 0 0
The 4 commonest variants from subfamily A and subfamily B are listed
isolates accounted for at each study site.Since fHBP is included in both 4CMenB (subfamily B type)
and bivalent rLP2086 (both subfamilies A and B), we deter-
mined the fHBP variants of isolates to add to the available
information on circulating strains of MenB in England.16,32,33B and non-serogroup B meningococcal carriage isolates that
riod.
n London Bristol Total
19 35 92
14 (73.7%) 34 (97.1%) 82 (89.1%)
0 15 (42.9%) 25 (27.2%)
5 (26.3%) 4 (11.4%) 25 (27.2%)
0 8 (22.9%) 14 (15.2%)
4 (21.1%) 4 (11.4%) 8 (8.7%)
5 (26.3%) 0 9 (9.8%)
3 (15.8%) 0 3 (3.3%)
0 0 2 (2.2%)
2 (10.5%) 0 2 (2.2%)
0 0 1 (1.1%)
40 107 280
20 (50.0%) 65 (60.7%) 171 (61.1%)
7 (17.5%) 30 (28.0%) 78 (27.9%)
6 (15%) 8 (7.5%) 22 (7.9%)
3 (7.5%) 3 (2.8%) 17 (6.1%)
1 (2.5%) 9 (8.4%) 15 (5.4%)
20 (50.0%) 39 (36/4%) 99 (35.4%)
10 (25%) 27 (25.2%) 64 (22.9%)
4 (10%) 4 (3.7%) 17 (6.1%)
1 (2.5%) 1 (0.9%) 5 (1.8%)
2 (5.0%) 2 (1.9%) 4 (1.4%)
, with the corresponding number (and proportion, in brackets) of
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family A much more frequently than subfamily B (89.1% vs.
9.8% of isolates). The relative proportion of carriage isolates
expressing variants from each subfamily has varied in the
literature, and indeed varied between the four geographic
sites in the current study. Isolates from cases of invasive dis-
ease overall carry fHBP subfamily B variants more
frequently,16,34 although in infants subfamily A strains appear
relatively more important.32 A vaccine using only subfamily B
may have less impact on carriage of these strains.
Once vaccines are in use, further studies will be required
to measure their impact on carriage, and our comparisons
between laboratory methods have implications for study
design. It is not surprising that we found seroagglutination,
which was originally developed for typing invasive isolates,
to be less useful for studies of the carriage state where
isolates may express capsule weakly or be unencapsulated
strains of low pathogenicity,12 although it does allow com-
parison with historical data. Many ‘non-groupable’ isolates
by seroagglutination (Fig. 2D) were successfully grouped by
real-time PCR, indicative of low capsule expression. In addi-
tion, seroagglutination is subjective, and use of whole cells
in the manufacture of commercial sera may result in non-
specific reactivity. During the course of this study, the inac-
curacy of serogroup detection by agglutination became
apparent (Table 2), and we suggest that molecular methods
are preferred for grouping isolates from carriage studies.
We explored the use of PCR analysis of swab transport
medium (direct swab PCR), as it would be logistically
attractive to remove the ‘bedside’ inoculation and culture
stages of carriage detection that are required for a
fastidious bacterium. However, compared to isolate PCR,
direct swab PCR had a sensitivity of 0.66 and would lead to
substantial underestimation of carriage. Although some
difference could be accounted for by sampling error, this
is more likely to reflect enrichment of genetic material
during growth.
This is the first study to have examined meningococcal
throat carriage longitudinally across school age students in
the UK. Carriage prevalence reflects both acquisition and
duration of carriage, variables which are difficult to ascer-
tain but important for modelling. Our study found a MenB
acquisition rate of 2.8/1000 person-months. A single nega-
tive swab however can result from sampling error or failure
of laboratory detection methods, so this may be an over-
estimation. Acquisition is very likely to be age-related, but
the small number of MenB acquisitions in the study meant
data had to be pooled across age groups. Approximately half
of carriers had MenB detected at two or more consecutive
visits in the 6 month study period, suggesting that carriage
usually persists for several months (although we did not
investigate whether these were the same or different
strains). This is in keeping with a study of a university
cohort10 which found 45% of carriers (33 individuals) were
persistent carriers over a 5e6 month period. Other studies
have suggested carriage duration may be much longer, for
example over 20 months when a statistical model was used
to take into account the limited sensitivity of pharyngeal
swabs, which may be only 60e80%.35 Increasing the number
of swabbing visits would be one way of improving the accu-
racy of data on carriage acquisition and duration, but in sec-
ondary school age children this is not very feasible. Weexperienced fairly high non-attendance for swabbing visits
(Fig. 1), likely related to dislike of the procedure and pres-
sure of school work and exams.
In conclusion, this study provides valuable current data
on meningococcal carriage in UK adolescents, demon-
strating a dominance of MenB and MenY, and low carriage
of MenC. Carriage rates rise gradually throughout adoles-
cence, suggesting that an immunisation programme de-
signed to reduce acquisition of MenB or MenY would be best
placed in the early teenage years or before. Studies
assessing vaccine impact face the challenges and limita-
tions of carriage detection methodologies, and we suggest
PCR of cultured isolates is the preferred method for
carriage detection at present.
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